布地奈德联合盐酸氨溴索雾化吸入在慢性阻塞性肺疾病急性加重期中的疗效观察(1)
[摘要] 目的 探讨布地奈德联合盐酸氨溴索雾化吸入在慢性阻塞性肺疾病急性加重期中的疗效。 方法 将82例慢性阻塞性肺疾病急性加重期患者随机分为对照组和研究组，每组41例。对照组采用抗感染、吸氧、解痉等常规治疗，研究组在常规治疗基础上使用布地奈德联合盐酸氨溴索雾化吸入。治疗7 d后，比较两组患者临床有效率、肺功能以及用药安全性。 结果 治疗后，两组患者FEV1和FEV1/FVC较治疗前均明显升高(P<0.05)，但与对照组相比，研究组FEV1和FEV1/FVC升高更加明显，差异具有统计学意义(P<0.05)。对照组和研究组的总有效率分别为70.7%和92.7%，差异具有统计学意义(P<0.05)。对照组和研究组的血、尿常规以及肝、肾功能未见明显异常。结论 布地奈德联合盐酸氨溴索雾化吸入在慢性阻塞性肺疾病急性加重期中的疗效确切，能改善患者肺功能，提高临床治疗总有效率。
[关键词] 慢性阻塞性肺疾病;布地奈德;盐酸氨溴索;雾化吸入;肺功能
[中图分类号] R563.9 [文献标识码] B [文章编号] 1673-9701(2018)36-0038-04
[Abstract] Objective To investigate the efficacy of budesonide combined with ambroxol hydrochloride nebulization in treatment of acute exacerbation of chronic obstructive pulmonary disease. Methods Eighty-two patients with acute exacerbation of chronic obstructive pulmonary disease were randomly divided into control group and study group， with 41 cases in each group. The control group was treated with anti-infective， oxygen-absorbing， antispasmodic and other conventional treatments. The study group was treated with budesonide and ambroxol hydrochloride nebulization on the basis of conventional treatment. After 7 days of treatment， the clinical efficacy， lung function， and medication safety of the two groups were compared. Results After treatment， the FEV1 and FEV1/FVC of the two groups were significantly higher than those before treatment(P<0.05)， but the increase of FEV1 and FEV1/FVC in the study group was more significant higher than those in the control group， and the difference was statistically significant(P<0.05). The total effective rates of the control group and the study group were 70.7% and 92.7%， respectively， and the difference was statistically significant(P<0.05). There were no significant abnormalities in blood and urine routine tests and liver and kidney function in the control group and the study group. Conclusion Budesonide combined with ambroxol hydrochloride nebulization in treatment of acute exacerbation of chronic obstructive pulmonary disease can improve the lung function of patients and improve the total effective rate of clinical treatment.
[Key words] Chronic obstructive pulmonary disease; Budesonide; Ambroxolhydrochloride; Nebulization; Pulmonary function
慢性阻塞性肺疾病(COPD)是肺部的一種慢性疾病，具有进行性加重的特点，临床致残率和致死率较高，给患者及其家庭以及社会带来沉重的负担[1-3]。研究显示，COPD由多种病因引起，临床主要表现为不完全可逆气流受限所导致的呼吸困难[1]。目前，根据患者临床症状的严重程度和发病的轻重缓急，COPD可分为稳定期和急性加重期[4]，而急性加重期患者肺部通气功能严重受损，甚至伴有全身的组织器官功能损伤[5]。研究表明，众多因素参与COPD急性加重期的发生和发展，而气道炎症占据关键作用[6-8]。因此，寻求有效措施降低气道的炎症反应，同时加强痰液的及时排出，对COPD急性加重期患者解除可逆部分的气流陷闭、改善肺部的通气功能具有重要意义[9-11]。布地奈德是一种可经鼻吸入的糖皮质激素，已被众多研究证实能扩张支气管、降低气道炎症反应，目前在临床上用于COPD 急性加重期的治疗取得了一定的疗效[12-14]。盐酸氨溴索是一种强效黏液性溶解剂，能有效稀释痰液、并减少气道炎症细胞的释放。因此，本研究通过前瞻、随机、对照的方法，探讨布地奈德联合盐酸氨溴索雾化吸入在COPD急性加重期中的临床疗效，以期为COPD的急性发作提供有效治疗措施。, 百拇医药(吴英 雷振东)
[关键词] 慢性阻塞性肺疾病;布地奈德;盐酸氨溴索;雾化吸入;肺功能
[中图分类号] R563.9 [文献标识码] B [文章编号] 1673-9701(2018)36-0038-04
[Abstract] Objective To investigate the efficacy of budesonide combined with ambroxol hydrochloride nebulization in treatment of acute exacerbation of chronic obstructive pulmonary disease. Methods Eighty-two patients with acute exacerbation of chronic obstructive pulmonary disease were randomly divided into control group and study group， with 41 cases in each group. The control group was treated with anti-infective， oxygen-absorbing， antispasmodic and other conventional treatments. The study group was treated with budesonide and ambroxol hydrochloride nebulization on the basis of conventional treatment. After 7 days of treatment， the clinical efficacy， lung function， and medication safety of the two groups were compared. Results After treatment， the FEV1 and FEV1/FVC of the two groups were significantly higher than those before treatment(P<0.05)， but the increase of FEV1 and FEV1/FVC in the study group was more significant higher than those in the control group， and the difference was statistically significant(P<0.05). The total effective rates of the control group and the study group were 70.7% and 92.7%， respectively， and the difference was statistically significant(P<0.05). There were no significant abnormalities in blood and urine routine tests and liver and kidney function in the control group and the study group. Conclusion Budesonide combined with ambroxol hydrochloride nebulization in treatment of acute exacerbation of chronic obstructive pulmonary disease can improve the lung function of patients and improve the total effective rate of clinical treatment.
[Key words] Chronic obstructive pulmonary disease; Budesonide; Ambroxolhydrochloride; Nebulization; Pulmonary function
慢性阻塞性肺疾病(COPD)是肺部的一種慢性疾病，具有进行性加重的特点，临床致残率和致死率较高，给患者及其家庭以及社会带来沉重的负担[1-3]。研究显示，COPD由多种病因引起，临床主要表现为不完全可逆气流受限所导致的呼吸困难[1]。目前，根据患者临床症状的严重程度和发病的轻重缓急，COPD可分为稳定期和急性加重期[4]，而急性加重期患者肺部通气功能严重受损，甚至伴有全身的组织器官功能损伤[5]。研究表明，众多因素参与COPD急性加重期的发生和发展，而气道炎症占据关键作用[6-8]。因此，寻求有效措施降低气道的炎症反应，同时加强痰液的及时排出，对COPD急性加重期患者解除可逆部分的气流陷闭、改善肺部的通气功能具有重要意义[9-11]。布地奈德是一种可经鼻吸入的糖皮质激素，已被众多研究证实能扩张支气管、降低气道炎症反应，目前在临床上用于COPD 急性加重期的治疗取得了一定的疗效[12-14]。盐酸氨溴索是一种强效黏液性溶解剂，能有效稀释痰液、并减少气道炎症细胞的释放。因此，本研究通过前瞻、随机、对照的方法，探讨布地奈德联合盐酸氨溴索雾化吸入在COPD急性加重期中的临床疗效，以期为COPD的急性发作提供有效治疗措施。, 百拇医药(吴英 雷振东)